Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

uniQure Announces Agreement with Genezen for Sale of Manufacturing Facility

Jul 01, 2024•almost 2 years ago

Contract Type

partnership

AmsterdamManufacturingBiotechnologyHealth Care

Description

uniQure N.V. has entered into an agreement for the sale of its global manufacturing facility in Lexington, Massachusetts to Genezen, a leading contract development and manufacturing organization specializing in the supply of retroviral vectors, lentiviral vectors, and adeno-associated virus (AAV) technologies. The sale represents an important milestone in uniQure’s ongoing effort to significantly reduce operating expenses and streamline its focus.

Company Information

Company

uniQure

Location

Amsterdam, North Holland, Netherlands

About

uniQure has been a pioneer in gene therapy manufacturing for the past 15 years. It has a commercially-licensed viral vector facility and a world-class team of employees. uniQure has established world-class manufacturing capabilities and is recognized for the first one-time gene therapy approved in the U.S. and Europe for the treatment of adults with severe and moderately severe Hemophilia B.

Predictive Intelligence
Strategic

ML-powered predictions for uniQure's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.